Voriconazole—a new therapeutic agent with an extended spectrum of antifungal activity

This publication has 26 references indexed in Scilit:

• Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive Aspergillosis
  Clinical Infectious Diseases, 2002
• Sporothrix schenckiisensitivity to voriconazole, itraconazole and amphotericin B
  Medical Mycology, 2001
• In Vitro Activities of Voriconazole, Itraconazole, and Amphotericin B against Blastomyces dermatitidis , Coccidioides immitis , and Histoplasma capsulatum
  Antimicrobial Agents and Chemotherapy, 2000
• Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities
  Clinical Infectious Diseases, 1998
• In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin
  Mycoses, 1998
• Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies
  Bone Marrow Transplantation, 1997
• The Safety and Efficacy of Amphotericin B Colloidal Dispersion in the Treatment of Invasive Mycoses
  Clinical Infectious Diseases, 1995
• The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study*
  Clinical Pharmacology & Therapeutics, 1995
• Successful Treatment of Fungal Infections in Neutropenic Patients with Liposomal Amphotericin (AmBisome)—A Report on 40 Cases from a Single Centre
  Leukemia & Lymphoma, 1992
• Treatment of invasive aspergillosis with itraconazole
  The American Journal of Medicine, 1989